Department of Urology, Maastricht University, Maastricht, The Netherlands.
Department of Urology, University Hospital RWTH Aachen, Aachen, Germany.
Am J Mens Health. 2022 Jul-Aug;16(4):15579883221115593. doi: 10.1177/15579883221115593.
Due to the COVID-19 pandemic, major congresses and many teaching opportunities as well as the usual visits from medical advisors of pharmaceutical firms have been postponed and canceled. The major trials of prostate cancer in the last 5 years in each state are shortly discussed providing a panoramic overview of the available evidence and data on prostate cancer treatment. Apalutamide, enzalutamide, and darolutamide have proven to have clinical benefits when added to androgen deprivation therapy for patients with nonmetastatic castration-resistant prostate cancer. In patients in the metastatic hormone-sensitive setting, next to docetaxel, abiraterone, enzalutamide, and apalutamide have been shown to significantly improve overall survival and progression-free survival in comparison to standard hormone therapy. In addition, docetaxel abiraterone and enzalutamide are widely used in the metastatic setting. For second-line therapy of metastasized prostate cancer patients who have received either docetaxel or abiraterone or enzalutamide, olaparib, cabazitaxel, radium, and lutetium therapy have been shown to be beneficial in selected patient groups.
由于 COVID-19 大流行，许多大会和教学机会以及制药公司的医学顾问的常规访问都被推迟和取消。简要讨论了过去 5 年每个州的前列腺癌主要临床试验，提供了关于前列腺癌治疗的现有证据和数据的全景概述。阿帕鲁胺、恩扎卢胺和达罗他胺已被证明在非转移性去势抵抗性前列腺癌患者的雄激素剥夺治疗中具有临床益处。在转移性激素敏感性患者中，除了多西他赛，阿比特龙、恩扎卢胺和阿帕鲁胺已被证明与标准激素治疗相比，显著提高了总生存期和无进展生存期。此外，多西他赛、阿比特龙和恩扎卢胺在转移性环境中广泛使用。对于已经接受多西他赛或阿比特龙或恩扎卢胺治疗的转移性前列腺癌患者的二线治疗，奥拉帕利、卡巴他赛、镭和镥治疗已被证明在选定的患者群体中有益。
